Barros-Oliveira Maria da Conceição, Costa-Silva Danylo Rafhael, Andrade Danielle Benigno de, Borges Umbelina Soares, Tavares Cléciton Braga, Borges Rafael Soares, Silva Janaína de Moraes, Silva Benedito Borges da
Posgraduate Program of Sciences and Health, Universidade Federal do Piauí, Teresina, PI, Brazil.
Department of Mastology, Hospital Getulio Vargas, Teresina, PI, Brazil.
Rev Assoc Med Bras (1992). 2017 Apr;63(4):371-378. doi: 10.1590/1806-9282.63.04.371.
Aromatase inhibitors have emerged as an alternative endocrine therapy for the treatment of hormone sensitive breast cancer in postmenopausal women. The use of third-generation inhibitors represented by exemestane, letrozol and anastrozole is currently indicated. Anastrozole is a nonsteroidal compound and a potent selective inhibitor of the aromatase enzyme. Although a few studies have shown that its pharmacodynamic and pharmacokinetic properties may be affected by interindividual variability, this drug has been recently used in all configurations of breast cancer treatment. In metastatic disease, it is currently considered the first-line treatment for postmenopausal women with estrogen receptor-positive breast tumors. Anastrozole has shown promising results in the adjuvant treatment of early-stage breast cancer in postmenopausal women. It has also achieved interesting results in the chemoprevention of the disease. Therefore, due to the importance of anastrozole both for endocrine treatment and chemoprevention of hormone-sensitive breast cancer in postmenopausal women, we proposed the current literature review in the SciELO and PubMed database of articles published in the last 10 years.
芳香化酶抑制剂已成为绝经后女性激素敏感性乳腺癌的一种替代内分泌治疗方法。目前推荐使用以依西美坦、来曲唑和阿那曲唑为代表的第三代抑制剂。阿那曲唑是一种非甾体化合物，是芳香化酶的强效选择性抑制剂。尽管一些研究表明其药效学和药代动力学特性可能受个体差异影响，但该药物最近已用于乳腺癌治疗的各种方案中。在转移性疾病中，它目前被认为是绝经后雌激素受体阳性乳腺肿瘤女性的一线治疗药物。阿那曲唑在绝经后女性早期乳腺癌的辅助治疗中已显示出有前景的结果。它在该疾病的化学预防方面也取得了令人感兴趣的结果。因此，鉴于阿那曲唑对绝经后女性激素敏感性乳腺癌的内分泌治疗和化学预防都很重要，我们在SciELO和PubMed数据库中对过去10年发表的文章进行了本次文献综述。
